1Mukharram A.Musaeva, 2Dinara A.Parpibaeva, 3Muborak S.Salaeva, 4Nargiza D.Salimova
1Assistant of the simulation training department of the Tashkent Medical Academy, Tashkent, Uzbekistan
2Doctor of Medical Sciences, Associate Professor, Head of the Department of Simulation training, Tashkent Medical Academy, Tashkent, Uzbekistan
3Candidate of medical sciences, Associate Professor of the Department of Simulation training, Tashkent Medical Academy, Tashkent, Uzbekistan
4Candidate of medical sciences, Associate Professor of the Department of Simulation training, Tashkent Medical Academy, Tashkent, Uzbekistan
DOI : https://doi.org/10.47191/ijmra/v5-i5-13Google Scholar Download Pdf
ABSTRACT:
Today, diabetes mellitus is one of the most powerful risk factors for the development of cardiovascular diseases and its complications. [1] In 50% of patients with type 1 diabetes and in 80% of people with type 2 diabetes, early disability and premature death are recorded due to cardiovascular complications. People with diabetes are often at risk for strokes, heart attacks, and high blood pressure. In this regard, the main strategy for the treatment of patients with diabetes is to prevent the development of cardiovascular complications, which includes strict control of glycemia, blood pressure, as well as antiplatelet and lipid-lowering therapy.
Despite the fact that strict glycemic control alone does not reduce the risk of myocardial infarction and mortality from it, most epidemiological and pathophysiological studies indicate a worse prognosis and a higher incidence of cardiovascular complications in chronic hyperglycemia. The use of a fixed combination of sitagliptin / metformin is one of the preferred options in the treatment of type 2 diabetes in patients with a high risk of cardiovascular disease due to the presence of type 4 dipeptidyl peptidase inhibitors of cardio protective effects. In this paper, changes in the lipid spectrum in patients with ischemic heart disease and type 2 diabetes mellitus with varying degrees of cardiac output are related to the number of years the patient has had diabetes mellitus, sitagliptin / metformin and statin drugs changes depending on the dose are highlighted.
KEYWORDS:dipeptidyl peptidase-4 inhibitors, metformin, type 2 diabetes mellitus, heart failure, average ejection fraction, preserved ejection fraction, lipid spectrum, statin.
REFERENCES
1) Diabetes mellitus and cardiovascular diseases // Edited by Ametov A.S., Kurochkin I.O.
2) Ametov A.S., Pakus E.N. Efficacy and safety of the combination of metformin and sitagliptin in the treatment of patients with type 2 diabetes mellitus with obesity // Diabetes Mellitus 2010. No. 3. C. 62–65.
3) Algorithms of specialized medical care for patients with diabetes mellitus / Edited by I.I. Dedova, M.V. Shestakova, A.Yu. Mayorova. – 9th edition (updated). – M.; 2019. P. 214. DOI: 10.14341/DM221S1
4) Rustamova M.T., Salaeva M.S., Salimova N.D., Nurmatov D.Kh. Influence of risk factors for the development of renal dysfunction in patients with stable angina on the background of type II diabetes mellitus // Bulletin of the Association of Physicians of Uzbekistan, Tashkent. 2020. S. 16-19
5) Kubota A, Maeda H, Kanamori A, Matoba K, Jin Y, Minagawa F, et al. Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients. J Clin Med Res 2012; 4:309-13.
6) Sesti G, Avogaro A, Belcastro S, Bonora BM, Croci M, Daniele G, et al. . Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. Acta Diabetol. (2019) 56:605–17. 10.1007/s00592-018-1271-3
7) Gallwitz B. Novel therapeutic approaches in diabetes. Endocr Dev. (2016) 31:43–56. 10.1159/000439372
8) Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opin Pharmacother. (2013) 14:2047–58. 10.1517/14656566.2013.824966
9) Gerich JE. Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus. Mayo Clinic Proc. (2003) 78:447–56. 10.4065/78.4.447
10) Creutzfeldt W. The incretin concept today. Diabetology. (1979) 16:75–85. 10.1007/BF01225454
11) Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. (2018) 20(Suppl 1):5–21. 10.1111/dom.13129
12) Sesti G, Avogaro A, Belcastro S, Bonora BM, Croci M, Daniele G, et al. . Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. Acta Diabetol. (2019) 56:605–17. 10.1007/s00592-018-1271-3
Volume 05 Issue 05 MAY 2022
There is an Open Access article, distributed under the term of the Creative Commons Attribution – Non Commercial 4.0 International (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/), which permits remixing, adapting and building upon the work for non-commercial use, provided the original work is properly cited.
Our Services and Policies
Authors should prepare their manuscripts according to the instructions given in the authors' guidelines. Manuscripts which do not conform to the format and style of the Journal may be returned to the authors for revision or rejected.
The Journal reserves the right to make any further formal changes and language corrections necessary in a manuscript accepted for publication so that it conforms to the formatting requirements of the Journal.
International Journal of Multidisciplinary Research and Analysis will publish 12 monthly online issues per year,IJMRA publishes articles as soon as the final copy-edited version is approved. IJMRA publishes articles and review papers of all subjects area.
Open access is a mechanism by which research outputs are distributed online, Hybrid open access journals, contain a mixture of open access articles and closed access articles.
International Journal of Multidisciplinary Research and Analysis initiate a call for research paper for Volume 07 Issue 12 (December 2024).
PUBLICATION DATES:
1) Last Date of Submission : 26 December 2024 .
2) Article published within a week.
3) Submit Article : editor@ijmra.in or Online
Why with us
1 : IJMRA only accepts original and high quality research and technical papers.
2 : Paper will publish immediately in current issue after registration.
3 : Authors can download their full papers at any time with digital certificate.
The Editors reserve the right to reject papers without sending them out for review.
Authors should prepare their manuscripts according to the instructions given in the authors' guidelines. Manuscripts which do not conform to the format and style of the Journal may be returned to the authors for revision or rejected. The Journal reserves the right to make any further formal changes and language corrections necessary in a manuscript accepted for publication so that it conforms to the formatting requirements of the Journal.